Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 134

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 134
---
)      Others (3)                 
                                                                           (IFRS)                                                                                                                                                                                                
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                           (billions of yen)                                                                                                                                                                                     
  Revenue                                                                  ¥                                        4,581.6      ¥                                      ¥                                    ¥                                        ¥                 4,579.8  
  Cost of sales                                                                                                   (1,580.2)      —                                      —                                    —                                        (1.6)           (1,581.8)  
  Selling, general and administrative expenses                                                                    (1,104.8)      —                                      —                                    —                                        (0.3)           (1,105.0)  
  Research and development expenses                                        (730.2)                                               —                                      —                                    —                                        (0.1)                      
  Amortization of intangible assets associated with products               (548.2)                                               548.2                                  —                                    —                                        —                          
  Impairment losses on intangible assets associated with products (1)      (95.0)                                                —                                      95.0                                 —                                        —                          
  Other operating income (expenses)                                        (180.5)                                               —                                      —                                    184.3                                    (3.8)                      
  Operating profit                                                         ¥                                          342.6      ¥                                      ¥                                    ¥                                        ¥                 1,162.6  

___________

Notes:

(1) Intangible assets associated with products include in-process R& D (IPR& D).

(2) Other operating income/expenses include changes in fair value of financial assets and liabilities associated with contingent consideration arrangements, gains/losses on sales of property, plant and equipment and investment property, gain on divestment of business and subsidiaries, donations and contributions, rental income and lease expense for sublease, restructuring expenses, valuation reserves for pre-launch inventories, expenses for post-trial access, impairment of assets held for sale, legal provisions, write-offs of option assets and other operating income (expenses) non-recurring in nature.

(3) Others: revenue and other operating income (expenses) include JPY 1.7 billion of deferred revenue recognized from the asset sale to Teva Takeda Pharma Ltd. (“ Teva”) and JPY 3.8 billion of deferred gain from the business divestiture to Teva, respectively, triggered by the divestment of Teva shares in the fiscal